Congestive Heart Failure Proceedings of the Symposium on New Drugs and Devices October 30–31, 1986, Philadelphia, Pennsylvania

Congestive Heart Failure Proceedings of the Symposium on New Drugs and Devices October 30–31, 1986, Philadelphia, Pennsylvania / by J. Morganroth, E. Neil Moore.

About 2. 5 million individuals have congestive heart fai lure in the United States with over 400,000 new cases expected annually. Congestive heart failure also is one of the commonest causes for hospital admissions accounting for over 5 million hospital days per year. Despite the early recognition o...

Full description

Saved in:
Bibliographic Details
Main Authors: Morganroth, J. (Author), Moore, E. Neil (Author)
Corporate Author: SpringerLink (Online service)
Format: eBook
Language:English
Published: New York, NY : Springer US : Imprint: Springer, 1987.
Edition:1st ed. 1987.
Series:Developments in Cardiovascular Medicine, 75
Springer eBook Collection.
Subjects:
Cardiology.
Electronic resources (E-books)
Online Access:Click to view e-book
Holy Cross Note:Loaded electronically.
Electronic access restricted to members of the Holy Cross Community.
Table of Contents:
  • I Epidemiology, Therapeutic Endpoints
  • 1. The public health and clinical implications of the national increase in congestive heart failure
  • 2. Therapeutic endpoints in the treatment of congestive heart failure with systolic dysfunction
  • 3. Evaluation of ventricular function in patients with heart failure: invasive or noninvasive?
  • 4. Assessment of neurohormonal parameters in congestive heart failure: determination of sodium and water regulation
  • 5. The assessment of quality of life and exercise response in patients with chronic cardiac failure
  • Panel Discussion
  • II Preclinical Issues and Pro Arrhythmia Definitions
  • 6. Animal models of heart failure
  • 7. Electrophysiology in congestive heart failure animal models
  • 8. Noninvasive evaluation of proarrhythmia
  • 9. Criteria for proarrhythmia in patients with congestive heart failure: use of electrophysiologic testing
  • Panel Discussion
  • III FDA Endpoint Issues
  • 10. Are placebo-controlled trials necessary in the evaluation of new therapeutic agents in severe chronic heart failure?
  • 11. What the FDA requires for endpoint measures in congestive heart failure studies
  • 12. Design of trials to assess safety and effectiveness in Rx of CHF
  • Panel Discussion
  • IV Therapeutic Strategies
  • 13. How does congestive heart failure alter response to drugs?
  • 14 Status of vasodilators for heart failure
  • 15. Perspectives on the use of new phosphodiesterase inhibitors in the treatment of chronic cardiac failure
  • 16. Is there a role for beta-blockers in heart failure patients?
  • Panel Discussion
  • V Clinical Trial Issues
  • 17. What CHF trials have shown to date and what is needed?
  • 18. How to study sudden cardiac death as an endpoint in congestive heart failure trials
  • 19. Interpretation of clinical trials in patients with congestive heart failure
  • Panel Discussion
  • Participants.

Similar Items